La entrada El interés público prevalece: las resoluciones de precio y reembolso de medicamentos son confidenciales aparece primero en Faus Moliner.

GLI Pricing & Reimbursement 2025 includes the following sections for each of the 18 analyzed countries:

• Market overview;
• Financing and pricing of medicinal products;
• Policy issues that affect pricing and reimbursement; and
• Emerging trends

La entrada Global Legal Insights to: Pricing & Reimbursement 2025 aparece primero en Faus Moliner.

La entrada El interés público prevalece: las resoluciones de precio y reembolso de medicamentos son confidenciales aparece primero en Faus Moliner.

GLI Pricing & Reimbursement 2024 includes the following sections for each of the 18 analyzed countries:

• Market overview;
• Financing and pricing of medicinal products;
• Policy issues that affect pricing and reimbursement; and
• Emerging trends

La entrada Global Legal Insights to: Pricing & Reimbursement 2024 aparece primero en Faus Moliner.

GLI Pricing & Reimbursement 2023 includes the following sections for each of the 18 analyzed countries:

• Market overview;
• Financing and pricing of medicinal products;
• Policy issues that affect pricing and reimbursement; and
• Emerging trends

La entrada Global Legal Insights to: Pricing & Reimbursement 2023 aparece primero en Faus Moliner.

GLI Pricing & Reimbursement includes the following sections for each of the 18 analyzed countries:

• Market overview;
• Financing and pricing of medicinal products;
• Policy issues that affect pricing and reimbursement; and
• Emerging trends

La entrada Global Legal Insights to: Pricing & Reimbursement 2022 aparece primero en Faus Moliner.

GLI Pricing & Reimbursement includes the following sections for each of the 18 analyzed countries:

• Market overview;
• Financing and pricing of medicinal products;
• Policy issues that affect pricing and reimbursement; and
• Emerging trends

La entrada Global Legal Insights to: Pricing & Reimbursement 2021 aparece primero en Faus Moliner.

The third edition of Pricing & Reimbursement has been recently published and just like last year Jordi Faus, with the collaboration of Lluís Alcover and Joan Carles Bailach, has been in charge of the chapter dedicated to pricing and reimbursement in Spain.

GLI Pricing & Reimbursement includes the following sections for each of the 22 analyzed countries:

• Market overview;
• Financing and pricing of medicinal products;
• Policy issues that affect pricing and reimbursement; and
• Emerging trends

La entrada Global Legal Insights to: Pricing & Reimbursement 2020 aparece primero en Faus Moliner.

The GLI to: Pricing & Reimbursement 2019 covers Abstract, Market introduction/overview, Pharmaceutical pricing and reimbursement, Policy issues that affect pricing and reimbursement, Emerging trends, Successful market access and the year ahead in 22 jurisdictions.

La entrada Global Legal Insights to: Pricing & Reimbursement 2019” aparece primero en Faus Moliner.

The consultation launched by the MoH identifies the main features on which the amendment of the system will focus. The aim is to articulate objective and transparent criteria to determine the identity of medicines’ presentations in terms of active ingredient and administration route, in order to decide when they can be included in the same group.

Achieving this aim will require the legislator to dig deeper, avoiding overly simplistic criteria such as resorting unreservedly to the ATC classification. It must be recalled that, in this sense, the WHO has pronounced itself against using this classification when it comes to medicines funding.

On the other hand, the new rules must be strictly in line with the decisions of the Courts regarding this matter. To such extent, the Supreme Court has highlighted in several judgments that when the competent regulatory agency has indicated that two active ingredients are different, they should not be considered as equals for the purposes of their inclusion into the same group in the reference price system.

Another important change of course is the intention of the MoH to enable the creation of different groups for presentations having the same active ingredient but different administration devices, pharmaceutical forms or specific administration routes, provided that doing so entails a relevant clinical advantage. This modification is essential. If products having administration devices with very high costs such as pre-filled syringes or pre-filled pens are included in the same group, matching their lowest price, it will be impossible to maintain the most innovative presentations in the NHS, with the consequent damage for patients.

Logically, it is also proposed to revise upwards the minimum reference price for each presentation, as the current minimum reference price has proven to be insufficient. Finally, and most importantly, the information included in the Nomenclator (database for medicines included in the NHS) will be regulated in order to be publicly accessible.

In short, this is an opportunity to correct important deficiencies in the current system. Achieving an adequate balance between public savings and stimulating innovation can only bring benefits for all the operators of the system and, very specially for patients.

La entrada The future rules of the reference price system of medicines in the National Health System shall be submitted for consultation aparece primero en Faus Moliner.